NewsBenzingaLeerink Partners mantiene la recomendación de “Outperform” sobre CVS Health y rebaja el precio objetivo a 104 dólares. Leerink Partners mantiene la recomendación de “Outperform” sobre CVS Health y rebaja el precio objetivo a 104 dólares. Benzinga 2026.11.05 20:13 (GMT+0) Open on Benzinga Other news Wolfspeed: Still Bullish After A Post-Earnings Wipeout (NYSE:WOLF) Apple Flagged Supply Constraints and Rising Memory Costs Ahead of Its December Quarter. Here’s What to Know. Stock Indexes Routed on Capitulation out of Chipmakers and AI Stocks Diodes Sees Q4 Adj EPS $1.25-$1.45 vs $1.03 Est; Sees Sales $533.500M-$566.500M vs $505.967M Est Leerink Partners Maintains Market Perform on Amgen, Raises Price Target to $464 Drilling Tools Intl Q3 Adj. EPS $(0.01) Misses $0.04 Estimate, Sales $40.645M Miss $40.871M Estimate
Apple Flagged Supply Constraints and Rising Memory Costs Ahead of Its December Quarter. Here’s What to Know.
